Safety and efficacy of intravenous bimagrumab in inclusion body myositis: a phase 2b, randomised, double-blind, placebo-controlled study (RESILIENT)

Research output: Contribution to journalArticle

Abstract


Bibliographical metadata

Original languageEnglish
JournalThe Lancet Neurology
Publication statusAccepted/In press - 12 Apr 2019